NCT05967715

Brief Summary

Cardiovascular diseases are the number 1 cause of death globally, taking an estimated 17.9 million lives each year (31% of deaths worldwide). Hypertension, with 1.13 billion people affected worldwide, is the leading risk factor for global mortality. Physical inactivity is among the modifiable cardiovascular risk factors. While the beneficial effects of physical activity on cardiovascular system are widely known, the mechanisms involved are not completely understood. Both exercise training and hypertension are linked to inflammation. Furthermore, there is evidence that gut microbiota regulates inflammatory patterns. Recent investigations showed a relationship between exercise training and the composition/functionality of the gut microbiota. Anyway, the modification of the composition and functionality of the gut microbiota in hypertension due to the exercise training and the relative involvement of oxidative stress and inflammation are not completely understood. In literature an association between gut microbiota composition and arterial stiffness is described, in particular, the investigators observed both a direct correlation between arterial stiffness and abundances of bacteria associated with altered gut permeability and inflammation; and an inverse relationship between arterial stiffness, microbiota diversity, and abundances of bacteria associated with most fit microbiota composition. Anyway, while these association were stable in animal studies, in human studies none of the identified interventional trials was able to demonstrate this relationship. Of note, only half of human studies measured BP, and very few adjusted the vascular analyses for BP variation, which is a major determinant of arterial stiffness. This is a non-profit, monocentric, non-pharmacological interventional study, a randomized controlled trial with three intervention arms, partial double-blind, aiming to verify the hypothesis that, in hypertensive patients in primary prevention with cardiovascular risk factors, physical exercise favorably modifies the intestinal bacterial flora compared to the probiotic, with a positive impact on cardiovascular health, and to demonstrate that this involves inflammation modulation. There will be 3 intervention arms, with 1:1:1 stratified randomization by gender: 1. Administration of controlled physical activity training; 2. Administration of probiotic; 3. Administration of placebo. Arms 2 and 3 will be double-blind. The intervention will last for three months, followed by a 6-month follow-up period. Afterwards, the medical team may be contacted for further tests/assessments or simply for information about the participant's health status, for a total duration of 24 months. The investigators hypothesize that hypertensive patients in cardiovascular primary prevention have a dysbiotic gut microbial signatures, that could be a new marker of early vascular aging. Secondly, the investigators anticipate that exercise training will modify both gut microbiota and hemodynamic profile, and that a relationship exists between gut microbiota and hemodynamic modifications. Thirdly, the investigators expect that the beneficial effects of exercise training are driven by positive changes in the inflammatory modulators.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
75

participants targeted

Target at P25-P50 for not_applicable hypertension

Timeline
Completed

Started Apr 2023

Typical duration for not_applicable hypertension

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 3, 2023

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

June 16, 2023

Completed
2 months until next milestone

First Posted

Study publicly available on registry

August 1, 2023

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 2, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 2, 2026

Completed
Last Updated

August 1, 2023

Status Verified

July 1, 2023

Enrollment Period

3 years

First QC Date

June 16, 2023

Last Update Submit

July 21, 2023

Conditions

Keywords

hypertensiongut microbiotaexercise trainingphysical activitycentral hemodynamicsarterial stiffnesspulse wave velocity

Outcome Measures

Primary Outcomes (1)

  • To describe the modification of the gut microbiota composition and function after the exercise training compared to probiotic supplements and to placebo.

    Changes in measures of gut microbiota composition and function from time 0 to 3 months (alpha diversity, beta diversity, taxonomy, relative abundance of microbial genes and pathways)

    time 0 and 3 months

Secondary Outcomes (7)

  • To describe the association between gut microbiota patterns with impaired central hemodynamics

    time 0 and 3 months

  • To test the association of the systemic inflammation with the modification of gut microbiota composition/functionality.

    time 0 and 3 months

  • To test the modification of endothelial function after the exercise training in comparison to probiotic supplements and placebo.

    time 0, and 3 months

  • To identify the variation of the gut microbiota composition and function in the long term follow up after the intervention

    from 3 to 9 months.

  • To describe the association between gut microbiota patterns with impaired central hemodynamics in the long term follow up 6 months after the intervention

    at 9-mo follow up

  • +2 more secondary outcomes

Study Arms (3)

Exercise training

EXPERIMENTAL

high intensity interval training: thrice a week

Behavioral: exercise training

Probiotics

ACTIVE COMPARATOR

VSL#3# probiotic: twice daily

Other: Probiotics

Placebo

PLACEBO COMPARATOR

Comparator of the Probiotics arm

Other: Placebo

Interventions

high intensity interval training

Exercise training

VSL#3# Probiotic

Probiotics
PlaceboOTHER

Probiotic Placebo

Placebo

Eligibility Criteria

Age40 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Arterial hypertension\*;
  • Stable antihypertensive therapy in the last 2 months, with controlled blood pressure values;
  • Age 40-65 years;
  • Willing to sign the written informed consent;
  • Written and spoken Italian language comprehension.

You may not qualify if:

  • Atrial fibrillation;
  • Diabetes mellitus either type I or II;
  • Active cancer;
  • Inflammatory bowel disease;
  • Heart failure NYHA class III to IV;
  • Recent antibiotic or probiotic treatment in the previous month for any reason;
  • Recent myocardial infarction or hospital admission for any other reason in the previous 6 months;
  • Any other condition that the medical doctor (MD) considers to contraindicate the participation in an exercise program of High intensity;
  • Pulmonary disease requiring oxygen therapy;
  • Relevant neurological condition impairing motor or cognitive function;
  • Severe depressive disorder;
  • Pregnancy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Bologna

Bologna, 40138, Italy

RECRUITING

MeSH Terms

Conditions

HypertensionMotor Activity

Interventions

ExerciseProbiotics

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular DiseasesBehavior

Intervention Hierarchy (Ancestors)

Motor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological PhenomenaDietary SupplementsFoodDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Central Study Contacts

Davide Agnoletti, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Only for the "probiotics" and "placebo" arms
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

June 16, 2023

First Posted

August 1, 2023

Study Start

April 3, 2023

Primary Completion

April 2, 2026

Study Completion

April 2, 2026

Last Updated

August 1, 2023

Record last verified: 2023-07

Data Sharing

IPD Sharing
Will not share

Locations